# US Vasomotor Symptoms Market > US Vasomotor Symptoms Market Research Report By Therapy Type (Hormonal, Non-Hormonal) and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Stores) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 7.77% - **2024:** $ 844.2 Million - **2025:** $ 909.79 Million - **2035:** $ 1,923.14 Million - **Key Players:** Pfizer Inc (US), Bristol-Myers Squibb Company (US), AbbVie Inc (US), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd (IL), Hoffmann-La Roche Ltd (CH), Novartis AG (CH), AstraZeneca PLC (GB) **Report ID:** MRFR/HC/18538-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-vasomotor-symptoms-market-20085 --- ## Market Summary ## **US Vasomotor Symptoms Market Overview** As per MRFR analysis, the US Vasomotor Symptoms Market Size was estimated at 789.6 (USD Million) in 2023. The US Vasomotor Symptoms Market Industry is expected to grow from 844.2(USD Million) in 2024 to 1,824.2 (USD Million) by 2035. The US Vasomotor Symptoms Market CAGR (growth rate) is expected to be around 7.256% during the forecast period (2025 - 2035). ### **Key US Vasomotor Symptoms Market Trends Highlighted** The US Vasomotor Symptoms Market is experiencing a notable shift as awareness around menopause and its associated symptoms increases. With more focus on women's health issues, particularly following research and advocacy campaigns, there is a growing recognition of vasomotor symptoms, such as hot flashes and night sweats, which affect a significant portion of the female population nearing or experiencing menopause. This has driven demand for effective treatment options, which has prompted pharmaceutical companies to research and develop both hormone replacement therapies and non-hormonal alternatives to target these symptoms. In recent times, there has also been a rise in preference for holistic and natural remedies, reflecting a broader trend in health and wellness. Many women are seeking non-invasive treatments such as herbal supplements, lifestyle changes, and alternative therapies, which provides an opportunity for companies to diversify their product lines to meet these preferences. Additionally, telehealth services are gaining traction, allowing women to consult healthcare providers from the comfort of their homes. This trend has been accelerated by the COVID-19 pandemic, underlining the need for accessible healthcare solutions in the US. Furthermore, the increasing influence of social media and online communities has encouraged open discussions about menopause, leading to greater visibility and understanding of vasomotor symptoms. This cultural shift supports both market growth and the exploration of opportunities in education and support resources. In summary, the US market is poised for innovation and expansion as it adapts to changing consumer preferences, and increased awareness promotes better treatment options for vasomotor symptoms. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **US Vasomotor Symptoms Market Drivers** #### **Increasing Awareness of Vasomotor Symptoms** There is a growing awareness regarding vasomotor symptoms, especially among women undergoing menopause. Organizations such as the North American Menopause Society (NAMS) have been actively educating healthcare providers and the public about the implications of menopause-related symptoms, which affect approximately 80% of women at some point in their lives. This increased awareness is leading to more women seeking medical advice and treatment. Moreover, public health campaigns have been conducted to highlight the impact of vasomotor symptoms on the quality of life, prompting discussions around management options. The US government also supports initiatives focusing on women's health, which is expected to bolster the US [Vasomotor Symptoms Market](../../../reports/vasomotor-symptoms-market-9810) Industry as healthcare providers are more equipped to address these symptoms, stimulating demand for treatment and care solutions. #### **Growing Demand for Hormone Replacement Therapy** The demand for Hormone Replacement Therapy (HRT) is on the rise in the United States, driven by an increasing incidence of vasomotor symptoms during menopause. According to the US Department of Health and Human Services, it is estimated that around 6,000 women enter menopause each day in the US. This translates to a significant number of women who may seek relief through HRT. The American College of Obstetricians and Gynecologists supports this demand by recommending HRT as an effective treatment for severe symptoms, leading to wider acceptance and use of therapies in practice. With more healthcare providers offering HRT and the growing emphasis on effective symptom management, this trend contributes positively to the growth trajectory of the US Vasomotor Symptoms Market Industry. #### **Advancements in Treatment Options** Recent advancements in treatment options for vasomotor symptoms are also driving market growth in the US. Innovative therapies, including selective serotonin reuptake inhibitors (SSRIs) and newer non-hormonal treatments, are becoming more widely available. Clinical studies have shown that these alternatives can effectively manage symptoms for women who prefer to avoid traditional HRT, creating a more tailored approach to treatment. Institutions such as the National Institutes of Health (NIH) are actively funding research into these new therapies, which has resulted in new FDA-approved options that enhance patient outcomes. As a result, the availability of these advanced treatment modalities is expected to further expand the US Vasomotor Symptoms Market Industry as healthcare providers consider various treatment regimens to best serve their patients. #### **Increased Healthcare Expenditure on Women’s Health** There has been a notable increase in healthcare expenditure targeting women's health issues in the United States. According to the Centers for Medicare and Medicaid Services, expenditures on women's health are projected to rise significantly in the coming years, reflecting broader societal recognition of women's health concerns, including vasomotor symptoms. This increase in funding is paving the way for improved access to care and treatment for women experiencing these symptoms. Furthermore, health insurance plans are increasingly recognizing the necessity of covering treatments for menopausal symptoms, thereby reducing out-of-pocket costs for patients. This supportive healthcare landscape creates continued growth prospects in the US Vasomotor Symptoms Market Industry, providing more women with the resources they need to manage symptoms effectively. ## **US Vasomotor Symptoms Market Segment Insights** ### **Vasomotor Symptoms Market Therapy Type Insights** The US Vasomotor Symptoms Market is experiencing notable growth, driven by the increasing prevalence of symptoms associated with hormonal changes, particularly during menopause. In this context, the Therapy Type segment is principally divided into two critical categories Hormonal and Non-Hormonal therapies. Hormonal therapies, which primarily involve the administration of estrogen, play a significant role in alleviating vasomotor symptoms such as hot flashes and night sweats. These therapies are often considered the first line of treatment due to their efficacy in managing symptoms effectively. However, there are also concerns regarding the long-term safety and side effects associated with hormonal treatments, which opens up a growing market for Non-Hormonal therapies. Non-Hormonal alternatives, including selective serotonin reuptake inhibitors (SSRIs) and other medications, provide patients with viable options who may be at risk of adverse effects from hormone therapy or who prefer to abstain from hormonal treatments altogether. This dynamic creates a diversified approach to treatment within the market. With new research and developments continually emerging, the adoption rate of both Therapy Types is influenced by patient preferences and clinical recommendations. The rising awareness of menopause and its associated symptoms has led to increased demand for effective treatment options, resulting in a robust growth in the US Vasomotor Symptoms Market. Moreover, this segment benefits from an emphasis on personalized medicine, allowing for tailored treatment regimens based on individual patient needs and medical history. The integration of technology, such as telehealth services, further enhances patient access to treatments, making it easier to obtain necessary prescriptions or consultations. As a result, both Hormonal and Non-Hormonal therapies are crucial in addressing the needs of women experiencing vasomotor symptoms, ensuring a comprehensive approach to management and treatment in a rapidly evolving market landscape. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Vasomotor Symptoms Market Distribution Channel Insights** The Distribution Channel segment of the US Vasomotor Symptoms Market is crucial, encompassing various avenues through which products reach consumers. Hospital pharmacies play a significant role in ensuring that patients undergoing treatment for vasomotor symptoms receive medications quickly and efficiently, serving as a vital touchpoint for prescription management. Retail pharmacies provide convenience and accessibility to the general public, often being the first point of contact for patients seeking relief from symptoms associated with menopause. The rise of online stores is transforming the marketplace, catering to the growing trend of e-commerce where patients can discreetly acquire products from the comfort of their homes. This shift towards online purchasing is driven by increased internet penetration and the growing preference for convenience among consumers. Overall, each distribution channel holds distinct importance in the US Vasomotor Symptoms Market, contributing to a balanced and comprehensive approach that enhances product availability and patient access, aligning with broader trends in the healthcare industry towards improved patient-centric service delivery. ## **US Vasomotor Symptoms Market Key Players and Competitive Insights** The competitive landscape of the US Vasomotor Symptoms Market is characterized by a dynamic interplay of innovation, strategic alliances, and market expansion efforts by key players. This market segment, primarily driven by the demand for effective treatments for symptoms associated with menopause, has attracted significant attention from pharmaceutical companies looking to enhance their product offerings. The presence of well-established organizations alongside emerging companies has led to a diverse range of therapies being developed to address the variegated needs of patients experiencing vasomotor symptoms. Analysis of this competitive environment reveals trends in product development, regulatory approvals, and market penetration strategies that are shaping the evolution of the sector in the United States. ### **Key Companies in the US Vasomotor Symptoms Market Include** ## **US Vasomotor Symptoms Market Industry Developments** The US Vasomotor Symptoms Market has seen significant recent activity, particularly regarding advancements and partnerships among leading pharmaceutical companies. Bristol Myers Squibb, AstraZeneca, Novartis, and others are noted for their ongoing Research and Development efforts, targeting innovative treatments for menopausal symptoms. In August 2023, Merck announced a strategic collaboration with Horizon Therapeutics, focusing on an emerging treatment that aims to alleviate vasomotor symptoms associated with menopause. Additionally, Eli Lilly has expanded its product portfolio with a new formulation aimed at reducing hot flashes, securing a competitive edge in the market. There have also been reports of industry growth, driven by increased awareness and diagnosis of vasomotor symptoms, with the market valuation expected to exceed $4 billion by 2025. Significant occurrences from the past few years include Sanofi's acquisition of a portfolio from another pharmaceutical company in May 2022, enhancing its position in this niche therapeutic area. The ongoing regulatory support from the Food and Drug Administration encourages innovation, prompting companies like Pfizer and Amgen to invest further in the landscape. Overall, the market shows robust potential, influenced by strong corporate investments and increasing patient demand. ## **US Vasomotor Symptoms Market Segmentation Insights** ### **Vasomotor Symptoms Market Therapy Type Outlook** ### **Vasomotor Symptoms Market Distribution Channel Outlook** ## Market Drivers ### Growing Aging Population The increasing aging population in the US is a primary driver for the vasomotor symptoms market. As individuals age, particularly women entering menopause, the prevalence of vasomotor symptoms such as hot flashes and night sweats rises significantly. According to the US Census Bureau, by 2030, approximately 20% of the population will be over 65 years old, leading to a higher demand for effective management solutions. This demographic shift suggests a potential market expansion, as healthcare providers seek to address the needs of older patients experiencing these symptoms. The vasomotor symptoms market is likely to see a surge in product development and innovation aimed at this growing segment, including both hormonal and non-hormonal therapies. ### Rising Healthcare Expenditure The rising healthcare expenditure in the US is another critical driver for the vasomotor symptoms market. As healthcare spending continues to increase, patients are more likely to seek medical advice and treatment for their symptoms. According to the Centers for Medicare & Medicaid Services, national health spending is projected to grow at an average rate of 5.4% annually, reaching nearly $6 trillion by 2027. This trend indicates that patients will have greater access to healthcare services, including those addressing vasomotor symptoms. Consequently, the vasomotor symptoms market is expected to benefit from increased patient engagement and a willingness to invest in effective treatment solutions. ### Emergence of Telehealth Services The emergence of telehealth services is transforming the landscape of the vasomotor symptoms market. With the growing acceptance of remote healthcare consultations, patients can now access specialized care from the comfort of their homes. This trend is particularly beneficial for women experiencing vasomotor symptoms, as it reduces barriers to seeking treatment. The vasomotor symptoms market is likely to see an increase in telehealth platforms offering consultations and treatment plans tailored to individual needs. As telehealth continues to gain popularity, it may lead to a broader reach and improved patient outcomes, potentially driving market growth in the coming years. ### Advancements in Treatment Options Recent advancements in treatment options for vasomotor symptoms are propelling the market forward. Innovative therapies, including new non-hormonal medications and lifestyle interventions, are gaining traction among healthcare providers and patients alike. The vasomotor symptoms market is witnessing a shift towards personalized medicine, where treatments are tailored to individual patient profiles. This trend is supported by clinical studies demonstrating the efficacy of various treatment modalities, which may lead to increased patient adherence and satisfaction. As a result, the market is expected to grow, with estimates suggesting a compound annual growth rate (CAGR) of around 6% over the next five years. ### Increased Focus on Women's Health The heightened focus on women's health issues in recent years has significantly impacted the vasomotor symptoms market. Advocacy groups and healthcare organizations are increasingly emphasizing the importance of addressing menopausal symptoms, leading to greater awareness and education among both healthcare providers and patients. This shift is likely to result in more women seeking treatment for vasomotor symptoms, thereby expanding the market. The vasomotor symptoms market is responding to this demand by developing targeted marketing strategies and educational campaigns aimed at informing women about available treatment options. This increased focus may contribute to a projected market growth of approximately 5% annually. ## Future Outlook The [Vasomotor Symptoms Market](https://www.marketresearchfuture.com/reports/vasomotor-symptoms-market-9810) is projected to grow at a 7.77% CAGR from 2025 to 2035, driven by increasing awareness and innovative treatment options. **New opportunities:** - Development of telehealth platforms for remote patient monitoring Investment in personalized medicine targeting specific demographics Expansion of over-the-counter treatment options for self-management By 2035, the market is expected to achieve substantial growth, reflecting evolving consumer needs and treatment advancements. ## Segment Insights ### By Type: Hormonal (Largest) vs. Non-Hormonal (Fastest-Growing) In the US vasomotor symptoms market, the distribution of market share between hormonal and non-hormonal treatments reveals hormonal therapies as the dominant choice among consumers, reflecting their established efficacy and historical usage. Non-hormonal treatments, while currently holding a smaller share, are rapidly gaining traction due to increasing awareness and preference for non-invasive options among patients. Growth trends indicate that non-hormonal treatments are emerging as the fastest-growing segment within the market, driven by a rising number of health-conscious individuals seeking alternatives to hormonal therapies. Factors such as changing societal attitudes towards health and wellness, along with advancements in non-hormonal formulations, are contributing to the increasing adoption of these treatments, signaling a shift in patient preferences. Type: Hormonal (Dominant) vs. Non-Hormonal (Emerging) Hormonal therapies remain the dominant force in the segment, known for their effectiveness in alleviating vasomotor symptoms associated with menopause. These treatments are often associated with well-established protocols and significant clinical backing, making them a preferred choice for many healthcare providers. In contrast, non-hormonal treatments are rapidly emerging as a viable alternative. They appeal particularly to those who are hesitant about hormonal interventions due to potential side effects. The growing demand for tailored treatment options in the US vasomotor symptoms market is fostering innovation in non-hormonal therapies, which are becoming increasingly recognized for their potential benefits, thus marking a significant shift in treatment paradigms. ### By Distribution Channel: Retail Pharmacies (Largest) vs. Online Stores (Fastest-Growing) In the US vasomotor symptoms market, the distribution of revenue among different channels is diverse, with retail pharmacies holding the largest share. These pharmacies provide convenience and accessibility for patients seeking treatment, contributing significantly to their dominance in the segment. Online stores are rapidly gaining traction as a growing alternative, reflecting changing consumer behavior and preferences, especially among younger demographics who prefer the convenience of purchasing medications online. The growth trends in the distribution channel segment are primarily driven by the increasing acceptance of e-commerce and online shopping. The COVID-19 pandemic has accelerated the shift towards online platforms, as patients seek safe and reliable options for acquiring their medications. Retail pharmacies remain essential for immediate access, while online stores are positioned as a flexible solution for those seeking privacy and discretion in managing their vasomotor symptoms. Retail Pharmacies (Dominant) vs. Online Stores (Emerging) Retail pharmacies serve as the dominant force in the distribution channel segment due to their wide network and established trust among consumers. They offer immediate access to medications and often provide additional health services, making them a preferred choice for many patients. In contrast, online stores represent an emerging segment that is rapidly evolving, catering to a growing demand for convenience and accessibility. The ability to discreetly order medications and have them delivered directly to one's home appeals to a significant portion of the market, particularly among tech-savvy consumers. These emerging platforms are increasingly integrating telehealth services, further enhancing their attractiveness in the US vasomotor symptoms market. ## Competitive Benchmarking The vasomotor symptoms market is characterized by a dynamic competitive landscape, driven by increasing awareness of menopausal health and the demand for effective treatment options. Key players such as Pfizer Inc (US), AbbVie Inc (US), and Bristol-Myers Squibb Company (US) are actively shaping the market through strategic initiatives. Pfizer Inc (US) focuses on innovation in hormone replacement therapies, while AbbVie Inc (US) emphasizes its portfolio expansion through acquisitions and partnerships. Bristol-Myers Squibb Company (US) is leveraging its research capabilities to develop novel therapies, thereby enhancing its competitive positioning. Collectively, these strategies contribute to a robust competitive environment, fostering advancements in treatment options for vasomotor symptoms. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for diverse strategies, enabling companies to cater to specific consumer needs while maintaining competitive pressure on pricing and innovation. In October 2025, AbbVie Inc (US) announced a strategic partnership with a leading biotechnology firm to co-develop a new treatment for vasomotor symptoms. This collaboration is expected to leverage advanced research capabilities and accelerate the development timeline, potentially positioning AbbVie as a frontrunner in the market. The strategic importance of this partnership lies in its potential to enhance AbbVie's product offerings and address unmet needs in the treatment landscape. In September 2025, Pfizer Inc (US) launched a digital health initiative aimed at improving patient engagement and adherence to vasomotor symptom treatments. This initiative utilizes mobile applications and telehealth services to provide personalized support to patients. The strategic significance of this move is evident in its alignment with current trends towards digitalization in healthcare, which may enhance patient outcomes and foster brand loyalty. In August 2025, Bristol-Myers Squibb Company (US) expanded its clinical trial program for a novel therapy targeting vasomotor symptoms, indicating a strong commitment to research and development. This expansion not only underscores the company's focus on innovation but also reflects a broader trend within the industry towards investing in clinical research to bring new therapies to market. The implications of this strategy could be substantial, as successful trials may lead to new treatment options that address the needs of a growing patient population. As of November 2025, the competitive trends in the vasomotor symptoms market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in treatment development. Strategic alliances are becoming more prevalent, allowing companies to pool resources and expertise to enhance their market positions. Looking ahead, competitive differentiation is likely to evolve, shifting from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition may ultimately lead to improved patient outcomes and a more sustainable market environment. ## Recent News & Developments The US Vasomotor Symptoms Market has seen significant recent activity, particularly regarding advancements and partnerships among leading pharmaceutical companies. Bristol Myers Squibb, AstraZeneca, Novartis, and others are noted for their ongoing Research and Development efforts, targeting innovative treatments for menopausal symptoms. In August 2023, Merck announced a strategic collaboration with Horizon Therapeutics, focusing on an emerging treatment that aims to alleviate vasomotor symptoms associated with menopause. Additionally, Eli Lilly has expanded its product portfolio with a new formulation aimed at reducing hot flashes, securing a competitive edge in the market. There have also been reports of industry growth, driven by increased awareness and diagnosis of vasomotor symptoms, with the market valuation expected to exceed $4 billion by 2025. Significant occurrences from the past few years include Sanofi's acquisition of a portfolio from another pharmaceutical company in May 2022, enhancing its position in this niche therapeutic area. The ongoing regulatory support from the Food and Drug Administration encourages innovation, prompting companies like Pfizer and Amgen to invest further in the landscape. Overall, the market shows robust potential, influenced by strong corporate investments and increasing patient demand. ## Report Scope | MARKET SIZE 2024 | 844.2(USD Million) | | --- | --- | | MARKET SIZE 2025 | 909.79(USD Million) | | MARKET SIZE 2035 | 1923.14(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.77% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Pfizer Inc (US), Bristol-Myers Squibb Company (US), AbbVie Inc (US), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd (IL), Hoffmann-La Roche Ltd (CH), Novartis AG (CH), AstraZeneca PLC (GB) | | Segments Covered | Type, Distribution Channel | | Key Market Opportunities | Emerging therapies targeting hormonal balance present opportunities in the vasomotor symptoms market. | | Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the vasomotor symptoms market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the overall market valuation of the US vasomotor symptoms market in 2024?** A: The overall market valuation was $844.2 Million in 2024. **Q: What is the projected market valuation for the US vasomotor symptoms market by 2035?** A: The projected valuation for 2035 is $1923.14 Million. **Q: What is the expected CAGR for the US vasomotor symptoms market during the forecast period 2025 - 2035?** A: The expected CAGR during the forecast period 2025 - 2035 is 7.77%. **Q: Which companies are considered key players in the US vasomotor symptoms market?** A: Key players include Pfizer Inc, Bristol-Myers Squibb Company, AbbVie Inc, Mylan N.V., Teva Pharmaceutical Industries Ltd, Hoffmann-La Roche Ltd, Novartis AG, and AstraZeneca PLC. **Q: What were the valuations for hormonal and non-hormonal treatments in the US vasomotor symptoms market in 2024?** A: In 2024, hormonal treatments were valued at $404.2 Million, while non-hormonal treatments were valued at $440.0 Million. **Q: How do the valuations for hospital pharmacies compare to retail pharmacies in the US vasomotor symptoms market?** A: In 2024, hospital pharmacies were valued at $169.26 Million, whereas retail pharmacies were valued at $337.08 Million. **Q: What is the projected growth for online stores in the US vasomotor symptoms market by 2035?** A: The valuation for online stores is projected to reach $745.02 Million by 2035. **Q: What were the valuations for retail pharmacies in 2024 and how do they compare to 2035 projections?** A: Retail pharmacies were valued at $337.08 Million in 2024, with projections indicating a rise to $785.56 Million by 2035. **Q: What segment of the US vasomotor symptoms market had the highest valuation in 2024?** A: In 2024, the non-hormonal segment had the highest valuation at $440.0 Million. **Q: How does the distribution channel of hospital pharmacies perform compared to online stores in the US vasomotor symptoms market?** A: Hospital pharmacies were valued at $169.26 Million in 2024, significantly lower than the $337.86 Million valuation for online stores. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-vasomotor-symptoms-market-20085*